Shira Dinner

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 12 papers. Top paper: “Blinatumomab for MRD-Negative Acute Lymphoblastic Leukemia in Adults”.

Blinatumomab for MRD-Negative Acute Lymphoblastic Leukemia in Adults

New England Journal of Medicine(2024)10.1056/nejmoa2312948

N/A

4.4DataRank · unranked

227 citations

Zhuoxin Sun, Ryan J. Mattison, Elisabeth Paietta, Kathryn G. Roberts, Yanming Zhang +37 more

Patient‐reported symptom monitoring and adherence to therapy in patients with newly diagnosed chronic myeloid leukemia

Cancer(2023)10.1002/cncr.35021

N/A

0.528DataRank · unranked

18 citations

Francesco Cottone, Betina R. Yanez, Vamsi Kota, Fausto Castagnetti, Giovanni Caocci +18 more

A phase 1 study of the CDK9 inhibitor voruciclib in relapsed/refractory acute myeloid leukemia and B-cell malignancies

Blood Advances(2024)10.1182/bloodadvances.2024014633

N/A

0.420DataRank · unranked

9 citations

Danielle M. Brander, Yesid Alvarado, Catherine Diefenbach, Daniel Nathan Egan, Shira Dinner +14 more

A phase 1 trial of venetoclax in combination with liposomal vincristine in patients with relapsed or refractory B‐cell or T‐cell acute lymphoblastic leukemia: Results from the ECOG‐ACRIN EA9152 protocol

eJHaem(2024)10.1002/jha2.991

N/A

0.297DataRank · unranked

5 citations

Ju‐Whei Lee, David F. Claxton, Elisabeth Paietta, Hassan B. Alkhateeb, Jae H. Park +8 more

The oral CDK9 inhibitor voruciclib combined with venetoclax for patients with relapsed/refractory acute myeloid leukemia

Blood Neoplasia(2025)10.1016/j.bneo.2025.100108

N/A

0.173DataRank · unranked

2 citations

Rachel J. Cook, Shira Dinner, Michael Keng, Kebede H. Begna, Nathalie Javidi‐Sharifi +9 more

Ibrutinib added to standard conditioning and as maintenance therapy following autologous hematopoietic stem cell transplantation for relapsed or refractory activated-B-cell type Diffuse Large B-cell lymphoma: primary analysis of the US intergroup double-blind randomized phase III study Alliance A051301/BMT-CTN 1201

Leukemia & lymphoma/Leukemia and lymphoma(2025)10.1080/10428194.2025.2525982

N/A

0DataRank · unranked

2 citations

Olivia Bobek, Eric D. Hsi, Timothy S. Fenske, Patrick J. Stiff, Brian T. Hill +12 more

Inhibitory effects of Tomivosertib in acute myeloid leukemia

Oncotarget(2021)10.18632/oncotarget.27952

N/A

0DataRank · unranked

10 citations

Gavin T. Blyth, Alain Mina, Ewa M. Kościuczuk, Blazej Dolniak, Shira Dinner +6 more

Derivation and external validation of a venous thromboembolism risk prediction model in asparaginase-treated ALL

Blood Advances(2025)10.1182/bloodadvances.2025017862

N/A

0DataRank · unranked

0 citations

Radhika Gangaraju, Wafik G. Sedhom, Eva N. Hamulyák, Tzu‐Fei Wang, Kristen M. O’Dwyer +30 more

Alliance A059102: A randomized phase II U.S. intergroup study of CHO(E)P versus CC-486-CHO(E)P versus duvelisib-CHO(E)P in previously untreated, CD30-negative, peripheral T-cell lymphomas.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.tps7593

N/A

0DataRank · unranked

4 citations

Susan M. Geyer, Stefan K. Barta, Jennifer E. Amengual, Travis Dockter, Chadwick Wright +8 more

Chemotherapy-free treatment with inotuzumab ozogamicin and blinatumomab for older adults with newly diagnosed, Ph-negative, CD22-positive, B-cell acute lymphoblastic leukemia: Alliance A041703.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.7006

N/A

0DataRank · unranked

48 citations

Jun Yin, Oudom Kour, Rebecca Teske, Wendy Stock, Kenneth Byrd +12 more

Results of a phase 3 study of IVO vs IO for previously untreated older patients (pts) with chronic lymphocytic leukemia (CLL) and impact of COVID-19 (Alliance).

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.7500

N/A

0DataRank · unranked

14 citations

Jun Yin, Jennifer R. Brown, Shira Dinner, Gerard Lozanski, Richard F. Little +15 more

Risk prediction for clonal cytopenia: multicenter real-world evidence

Blood(2024)10.1182/blood.2024024756

N/A

0DataRank · unranked

50 citations

Rami S. Komrokji, Najla Al‐Ali, Alexandra Regelson, Susan Geyer, Anand Patel +39 more